Neoral use in the cardiac transplant recipient (Q33920665)

30 July 2017

1 reference

title

Neoral use in the cardiac transplant recipient (English)

1 reference

30 July 2017

Valantine H

1

1 reference

PubMed ID

10814748

30 July 2017

language of work or name

English

0 references

publication date

1 May 2000

1 reference

Transplantation Proceedings

30 July 2017

1 reference

30 July 2017

32

1 reference

30 July 2017

3A Suppl

1 reference

30 July 2017

27S-44S

1 reference

Cyclosporine heart transplantation

30 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900862-9

7 January 2021

Multicenter evaluation of immunosuppressive regimens in heart transplantation. The Collaborative Transplant Study

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900862-9

7 January 2021

Safety, tolerability and efficacy of cyclosporine microemulsion in heart transplant recipients: a randomized, multicenter, double-blind comparison with the oil based formulation of cyclosporine--results at six months after transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900862-9

7 January 2021

The risk of coronary artery disease after heart transplantation is increased in patients receiving low-dose cyclosporine, regardless of blood cyclosporine levels.

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900862-9

7 January 2021

Metabolic risk factors for atherosclerosis in heart transplant recipients.

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900862-9

7 January 2021

Development of coronary artery disease in cardiac transplant patients receiving immunosuppressive therapy with cyclosporine and prednisone

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900862-9

7 January 2021

Targeting the alloimmune response for prevention of chronic graft loss: efficacy of new immunosuppressive drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900862-9

7 January 2021

Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900862-9

7 January 2021

Coronary artery intimal thickening in the transplanted heart. An in vivo intracoronary untrasound study of immunologic and metabolic risk factors.

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900862-9

7 January 2021

Risk factors for early mortality, acute rejection, and factors affecting first-year survival after heart transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900862-9

7 January 2021

Cardiac transplantation: three decades of experience define our challenge

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900862-9

7 January 2021

Effect of pravastatin on outcomes after cardiac transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900862-9

7 January 2021

Prognostic importance of intimal thickness as measured by intracoronary ultrasound after cardiac transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900862-9

7 January 2021

Can histopathology guide immunosuppression for cardiac allograft rejection in the light of new techniques?

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900862-9

7 January 2021

Echocardiographic indexes of rejection in pediatric cardiac transplant recipients managed without maintenance steroid immunosuppression

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900862-9

7 January 2021

Comparative bioavailability of Neoral and Sandimmune in cardiac transplant recipients over 1 year

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900862-9

7 January 2021

Neoral versus Sandimmun: clinical impact and modification of immunosuppressive therapy in cardiac transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900862-9

7 January 2021

Long-term safety and efficacy of Neoral in heart transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900862-9

7 January 2021

Cyclosporin pharmacokinetics in paediatric transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900862-9

7 January 2021

French multicenter study of Neoral conversion in heart transplant patients

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900862-9

7 January 2021

Clinical impact of Neoral in thoracic organ transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900862-9

7 January 2021

Neoral conversion in stable thoracic transplant patients leads to dose reduction

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900862-9

7 January 2021

Impact of age on clinical outcome and postlytic management strategies in patients treated with intravenous thrombolytic therapy. Results from the TIMI II Study. TIMI II Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900862-9

7 January 2021

CD40L (CD154) expression in human liver allografts during chronic ductopenic rejection

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900862-9

7 January 2021

Cyclosporine-associated end-stage nephropathy after cardiac transplantation: incidence and progression

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900862-9

7 January 2021

Cyclosporin nephrotoxicity following cardiac transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900862-9

7 January 2021

Progressive renal insufficiency following cardiac transplantation: cyclosporine, lipids, and hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900862-9

7 January 2021

Post-transplant diabetes mellitus. The role of immunosuppression

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900862-9

7 January 2021

Durable remission after aggressive chemotherapy for post-cardiac transplant lymphoproliferation

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900862-9

7 January 2021

Does early steroid withdrawal influence rejection and infection episodes during the first 2 years after heart transplantation?

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900862-9

7 January 2021

The use of antibodies against the IL-2 receptor in transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900862-9

7 January 2021

Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900862-9

7 January 2021

Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900862-9

7 January 2021

Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900862-9

7 January 2021

SDZ RAD, a new rapamycin derivative: synergism with cyclosporine

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900862-9

7 January 2021

Immunopharmacology of rapamycin

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900862-9

7 January 2021

A prospective trial of tacrolimus (FK 506) in clinical heart transplantation: intermediate-term results

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900862-9

7 January 2021

Incidence of humoral rejection in heart transplant recipients treated with tacrolimus or cyclosporine A

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900862-9

7 January 2021

Tacrolimus as a rescue immunosuppressant after heart and lung transplantation. The U.S. Multicenter FK506 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900862-9

7 January 2021

Treatment of nonhemodynamic compromising rejection: conventional approaches vs individualization/new immunosuppressive drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900862-9

7 January 2021

Recurrent or persistent cardiac allograft rejection: therapeutic options and recommendations

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2900862-9

7 January 2021

10.1016/S0041-1345(00)00862-9

Identifiers

DOI

1 reference

30 July 2017

1 reference

PubMed ID

10814748